NO20032483L - Kondenserte purinderivater som A<N>1<N/>-adenosinreseptor-antagonister - Google Patents

Kondenserte purinderivater som A<N>1<N/>-adenosinreseptor-antagonister

Info

Publication number
NO20032483L
NO20032483L NO20032483A NO20032483A NO20032483L NO 20032483 L NO20032483 L NO 20032483L NO 20032483 A NO20032483 A NO 20032483A NO 20032483 A NO20032483 A NO 20032483A NO 20032483 L NO20032483 L NO 20032483L
Authority
NO
Norway
Prior art keywords
receptor antagonists
adenosine receptor
purine derivatives
condensed purine
condensed
Prior art date
Application number
NO20032483A
Other languages
English (en)
Norwegian (no)
Other versions
NO20032483D0 (no
Inventor
Chi Vu
Ko-Chung Lin
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20032483D0 publication Critical patent/NO20032483D0/no
Publication of NO20032483L publication Critical patent/NO20032483L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
NO20032483A 2000-12-01 2003-06-02 Kondenserte purinderivater som A<N>1<N/>-adenosinreseptor-antagonister NO20032483L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25065800P 2000-12-01 2000-12-01
PCT/US2001/044991 WO2002044182A1 (en) 2000-12-01 2001-11-30 Condensed purine derivatives as a1 adenosine receptor antagonists

Publications (2)

Publication Number Publication Date
NO20032483D0 NO20032483D0 (no) 2003-06-02
NO20032483L true NO20032483L (no) 2003-07-30

Family

ID=22948640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032483A NO20032483L (no) 2000-12-01 2003-06-02 Kondenserte purinderivater som A<N>1<N/>-adenosinreseptor-antagonister

Country Status (32)

Country Link
US (2) US6605601B2 (is)
EP (1) EP1347981B1 (is)
JP (2) JP2004514723A (is)
KR (1) KR20040011439A (is)
CN (1) CN100497340C (is)
AR (1) AR035400A1 (is)
AT (1) ATE394402T1 (is)
AU (2) AU2002219977B2 (is)
BG (1) BG107849A (is)
BR (1) BR0115833A (is)
CA (1) CA2430508C (is)
CZ (1) CZ20031513A3 (is)
DE (1) DE60133931D1 (is)
EA (1) EA009814B1 (is)
EE (1) EE200300260A (is)
ES (1) ES2305139T3 (is)
GE (1) GEP20094697B (is)
HU (1) HUP0400530A3 (is)
IL (1) IL156046A0 (is)
IS (1) IS6821A (is)
MX (1) MXPA03004857A (is)
MY (1) MY127120A (is)
NO (1) NO20032483L (is)
NZ (1) NZ526511A (is)
PL (1) PL362642A1 (is)
SK (1) SK6552003A3 (is)
TR (1) TR200300766T2 (is)
TW (1) TWI293301B (is)
UA (1) UA75625C2 (is)
WO (1) WO2002044182A1 (is)
YU (1) YU42903A (is)
ZA (2) ZA200304067B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047931A1 (en) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
YU42903A (sh) * 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina
WO2004074247A2 (en) * 2003-02-19 2004-09-02 Endacea, Inc. A1 adenosine receptor antagonists
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
CN1777608A (zh) * 2003-04-25 2006-05-24 协和发酵工业株式会社 稠合嘧啶衍生物
EP1620107A1 (en) * 2003-04-25 2006-02-01 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
EP1636229A4 (en) * 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
EP1863815A1 (en) * 2005-03-11 2007-12-12 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof
WO2007095161A2 (en) * 2006-02-14 2007-08-23 New York University Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
CA2648281A1 (en) * 2006-04-06 2007-10-18 Novacardia, Inc. Co-administration of adenosine a1 receptor antagonists and anticonvulsants
US7872017B2 (en) 2006-05-19 2011-01-18 Abbott Laboratories Fused bicycloheterocycle substituted azabicyclic alkane derivatives
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
JP5274455B2 (ja) 2006-06-23 2013-08-28 インサイト コーポレイション Ｈｍ７４ａアゴニストとしてのプリノン誘導体
AU2007260851B2 (en) 2006-06-23 2013-01-17 Incyte Corporation Purinone derivatives as HM74a agonists
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
WO2008121893A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2011063268A2 (en) * 2009-11-19 2011-05-26 Biogen Idec Ma Inc Novel synthetic methods
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
EP3735413B1 (en) 2018-01-04 2022-07-06 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
EP0423805B1 (en) * 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Condensed purine derivatives
EP0884314B1 (en) 1991-09-23 2004-01-21 Florida State University Metal alkoxides
WO1998015555A1 (en) * 1996-10-07 1998-04-16 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
WO1998057651A1 (en) * 1997-06-18 1998-12-23 Discovery Therapeutics, Inc. Compositions and methods for preventing restenosis following revascularization procedures
AU4396899A (en) * 1998-07-02 2000-01-24 Kyowa Hakko Kogyo Co. Ltd. Remedies for diabetes
WO2001047931A1 (en) * 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Fused purine derivatives
YU42903A (sh) * 2000-12-01 2006-05-25 Biogen Inc. Kondenzovani derivati purina kao antagonisti a1 receptora adenozina

Also Published As

Publication number Publication date
TR200300766T2 (tr) 2004-09-21
AR035400A1 (es) 2004-05-26
EP1347981A1 (en) 2003-10-01
MY127120A (en) 2006-11-30
US6605601B2 (en) 2003-08-12
GEP20094697B (en) 2009-06-10
EA009814B1 (ru) 2008-04-28
US20030220358A1 (en) 2003-11-27
ZA200408755B (en) 2005-07-27
TWI293301B (en) 2008-02-11
US7022686B2 (en) 2006-04-04
PL362642A1 (en) 2004-11-02
BG107849A (bg) 2004-01-30
HUP0400530A2 (hu) 2004-06-28
ATE394402T1 (de) 2008-05-15
CN100497340C (zh) 2009-06-10
MXPA03004857A (es) 2003-08-19
EE200300260A (et) 2003-08-15
NZ526511A (en) 2005-04-29
IL156046A0 (en) 2003-12-23
UA75625C2 (en) 2006-05-15
ES2305139T3 (es) 2008-11-01
DE60133931D1 (de) 2008-06-19
EA200300629A1 (ru) 2003-12-25
JP2004514723A (ja) 2004-05-20
NO20032483D0 (no) 2003-06-02
AU2002219977B2 (en) 2008-01-24
ZA200304067B (en) 2005-05-30
CZ20031513A3 (cs) 2003-09-17
CA2430508C (en) 2010-05-18
JP2010053148A (ja) 2010-03-11
HK1059927A1 (en) 2004-07-23
WO2002044182A1 (en) 2002-06-06
EP1347981B1 (en) 2008-05-07
BR0115833A (pt) 2003-10-28
SK6552003A3 (en) 2003-12-02
IS6821A (is) 2003-05-20
HUP0400530A3 (en) 2007-05-29
US20020111333A1 (en) 2002-08-15
KR20040011439A (ko) 2004-02-05
YU42903A (sh) 2006-05-25
CN1481387A (zh) 2004-03-10
AU1997702A (en) 2002-06-11
CA2430508A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
NO20032483L (no) Kondenserte purinderivater som A&lt;N&gt;1&lt;N/&gt;-adenosinreseptor-antagonister
DK1349839T3 (da) Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
NO20032482L (no) Forbindelser som er spesifikke overfor adenosin-A1, A2A og A&lt; N&gt;3-reseptor samt anvendelse derav
DE60119492D1 (de) Purinderivate
ATE267836T1 (de) Purinderivate
ATE309245T1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3- d)pyrimidin-derivate
DK1189916T3 (da) N-pyrazol A 2A-receptoragonister
DE60116260D1 (de) Antivirale azaindolderivate
NO20030353D0 (no) 4-Fenyl-pyridin-derivater som neurokinin-1-reseptor- antagonister
NO20022557D0 (no) 2,4-diaminopyrimidinforbindelser nyttige som immunosuppreserende midler
NO20032142L (no) Substituerte 2-fenylaminoimidazolin-fenylketon-derivater som IP-antagonister
NO20002036L (no) Cyklopentenderivater anvendbare som antagonister for motilinreseptoren
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
DK1347974T3 (da) Aminotriazolopyridinderivater som adenosinreceptorligander
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
NO20015662D0 (no) Oralt aktive A1-adenosinreseptorantagonister
UA4785S (uk) Упакування для клею «супер стар»
GB0010292D0 (en) A adenosine receptor agonists
NO20020311D0 (no) 1,4,5,6-tetrahydropyrimidinderivat som en vitronektininhibitor

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application